Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697240 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
A Phase 1 study, sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02697240 is a Phase 1 study that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT02697240, a Phase 1 study, has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Sickle cell disease is a genetic red blood cell disorder characterized by vaso-occlusion from sickling of red blood cells, that can lead to pain or organ complications such as acute chest syndrome. Sickle cell disease is associated with low amounts of nitric oxide, a compound important for dilating the blood vessel wall. Citrulline is a substance that is known to increase nitric oxide. The goal of this Phase I study are to find the highest safe dose of continuous IV citrulline that can be given to individuals with sickle cell disease experiencing a sickle cell pain crisis or acute chest syndrome without causing severe side effects.
Interventions
- DRUG Intravenous citrulline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02697240
The ClinicalTrials.gov registry entry for NCT02697240 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravenous citrulline is the first listed.
NCT02697240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02697240 about?
NCT02697240 is a clinical study titled "A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome". Sickle cell disease is a genetic red blood cell disorder characterized by vaso-occlusion from sickling of red blood cells, that can lead to pain or organ complications such as acute chest syndrome. Sickle cell disease is associated with low amounts of nitric oxide, a compound important for dilating ...
What is the current status of trial NCT02697240?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2016-02. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02697240?
The interventions under investigation include: Intravenous citrulline (DRUG).
Who is sponsoring clinical trial NCT02697240?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.